Distinct Association of MRE11 and ATM Co-Expression with Clinical Outcomes in Laryngeal Cancer
Oncology · 17.03.2026 · 1-12
DOI: 10.1159/000551450 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology, online erschienen am 17.03.2026. Verfasst von Zdenka Pechacova und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Radiation Oncology, First Faculty of Medicine, Charles University and Bulovka University Hospital, Prague, Czechia, zdenka.pechacova@bul…. Hauptthemen laut MEDLINE: Ataxia Telangiectasia Mutated Proteins, MRE11 Homologue Protein, Laryngeal Neoplasms. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Radiotherapy is a cornerstone of laryngeal cancer treatment. MRE11, a key component of the MRN complex, and the ATM protein are important elements of DNA repair. This study examines the impact of MRE11 and ATM on treatment outcomes in laryngeal cancer patients treated at Bulovka University Hospital in Prague.
Methods
This retrospective study included 108 patients with laryngeal cancer treated with radiotherapy. Immunohistochemical (IHC) analysis of pretreatment biopsy samples was performed to evaluate MRE11 and ATM expression and statistically estimate the impact on treatment outcomes.
Results
Statistically significant differences were found in subgroups of patients according to the IHC positivity of at least one of these two proteins. A statistically significant association was confirmed between IHC positivity for MRE11 or ATM protein (at least one of them) and better overall survival (OS; p < 0.001). IHC negativity for both proteins was found only in patients in clinical stage IV (p < 0.001) with the shortest OS confirmed in this subgroup of patients.
Conclusion
High IHC expression of MRE11 and ATM proteins was associated with earlier clinical stages and better treatment outcomes in laryngeal carcinoma, particularly when both proteins were elevated. The results point to the potential of MRE11 and ATM as predictors of treatment response, but more extensive molecular and clinical research would be needed to gain a more detailed insight.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Radiation Oncology, First Faculty of Medicine, Charles University and Bulovka University Hospital, Prague, Czechia, zdenka.pechacova@bulovka.cz.
- Department of Oncology, First Faculty of Medicine, Charles University and Thomayer University Hospital, Prague, Czechia.
- Department of Pathology and Anatomy, Bulovka University Hospital, Prague, Czechia.
- Bioptical Laboratory Ltd, Pilsen, Czechia.
- Institute of Radiation Oncology, First Faculty of Medicine, Charles University and Bulovka University Hospital, Prague, Czechia.
Zitieren
APA
Pechacova, Z., Lohynska, R., Spurkova, Z., Sedivec, V., Svajdler, M., Drbohlavova, T., Tesarova, P., & Pala, M. (2026). Distinct Association of MRE11 and ATM Co-Expression with Clinical Outcomes in Laryngeal Cancer. Oncology, 1-12. https://doi.org/10.1159/000551450
Vancouver
Pechacova Z, Lohynska R, Spurkova Z, Sedivec V, Svajdler M, Drbohlavova T, et al. Distinct Association of MRE11 and ATM Co-Expression with Clinical Outcomes in Laryngeal Cancer. Oncology. 2026:1-12. doi:10.1159/000551450
BibTeX
@article{Pechacova2026,
author = {Pechacova, Zdenka and Lohynska, Radka and Spurkova, Zuzana and Sedivec, Vratislav and Svajdler, Marian and Drbohlavova, Tereza and Tesarova, Petra and Pala, Miloslav},
title = {Distinct Association of MRE11 and ATM Co-Expression with Clinical Outcomes in Laryngeal Cancer},
journal = {Oncology},
year = {2026},
pages = {1--12},
doi = {10.1159/000551450}
}
EUVIMED